Literature DB >> 3484679

Dissociation of therapeutic and toxic effects of polyinosinic-polycytidylic acid admixed with poly-L-lysine and solubilized with carboxymethyl cellulose in tumor-bearing mice.

D Hartmann, J S Adams, A K Meeker, M A Schneider, B F Lenz, J E Talmadge.   

Abstract

In this paper, we describe a study of the therapeutic parameters (dose and schedule) and immunomodulatory activity (macrophage, natural killer cell, and T-cell number and function) of polyinosinic-polycytidylic acid admixed with poly-L-lysine and solubilized with carboxymethyl cellulose [poly(I,C)-LC] in the treatment of MBL-2 tumor ascites. Tumor-bearing mice received an optimal therapeutic protocol [100 micrograms poly(I,C)-LC administered twice a wk], a maximum tolerated dose [50 micrograms poly(I,C)-LC administered daily], or the optimal immunomodulatory protocol for normal mice [10 micrograms poly(I,C)-LC administered daily]. The percentage of tumor-associated macrophages and their cytotoxic activity correlated with host survival. In addition, splenic T-cell activity correlated with host survival, and splenic natural killer cell function had a near significant correlation with host survival. These results indicate that the optimal dose and schedule of poly(I,C)-LC for immunomodulation in tumor-bearing animals are also the optimal therapeutic protocol but have less toxicity than the maximum tolerated dose.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484679

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Antitumor effects of interleukin-2 and mismatched double-stranded RNA, individually and in combination, against a human malignant melanoma xenograft.

Authors:  H R Hubbell; H E Vargas; K L Tsujimoto; G D Gibson; E C Pequignot; R D Bigler; W A Carter; D R Strayer
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses.

Authors:  Christian Hotz; Marina Treinies; Ines Mottas; Laurin C Rötzer; Anne Oberson; Lorenzo Spagnuolo; Maurizio Perdicchio; Thibaud Spinetti; Tina Herbst; Carole Bourquin
Journal:  Oncoimmunology       Date:  2016-09-09       Impact factor: 8.110

3.  Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy.

Authors:  A Schomburg; H Kirchner; J Atzpodien
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

4.  Antitumor response to recombinant murine interferon gamma correlates with enhanced immune function of organ-associated, but not recirculating cytolytic T lymphocytes and macrophages.

Authors:  P L Black; H Phillips; H R Tribble; R Pennington; M Schneider; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.